NEOG · XBRL financial data

Neogen financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NEOG's year ends in late May)

In millions of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023†May 31, 2023	FY 2024May 31, 2024	FY 2025May 31, 2025	FY 2026May 31, 2026
Revenue from contracts with customers	468	527	822	924	895	870
Cost of revenue	—	—	416	460	473	—
Cost of goods and services sold	253	284	416	460	473	462
Gross profit	215	243	406	464	421	409
Research and development	16	17	26	22	21	18
General and administrative	51	83	201	200	218	245
Total operating expenses	141	184	368	405	1,482	430
Operating income (loss)	74	59	38	59	(1,061)	(22)
Interest expense	—	—	27	42	38	24
Other income (expense)	(1)	0	(7)	(6)	(4)	(6)
Income tax expense (benefit)	14	12	1	(5)	(41)	(1)
Net income (loss)	61	48	(23)	(9)	(1,092)	(8)
Earnings per share, basic USD per share	0.57	0.45	(0.12)	(0.04)	(5.03)	(0.04)
Earnings per share, diluted USD per share	0.57	0.45	(0.12)	(0.04)	(5.03)	(0.04)
Weighted average shares, basic millions of shares	106	108	189	216	217	218
Weighted average shares, diluted millions of shares	107	108	189	216	217	218

† Share count changed about 2x in the period ending 2023-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NEOG's year ends in late May)

In millions of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023†May 31, 2023	FY 2024May 31, 2024	FY 2025May 31, 2025	FY 2026May 31, 2026
Cash and cash equivalents	76	44	163	171	129	186
Marketable securities	305	337	82	0	0	—
Accounts receivable	92	100	153	173	153	147
Inventory	101	122	134	189	191	144
Prepaid and other current assets	18	24	53	56	53	60
Total current assets	591	627	586	589	577	605
Property and equipment, net	100	111	199	277	339	330
Right-of-use asset	2	3	12	15	17	17
Goodwill	131	143	2,137	2,136	1,065	1,047
Total assets	920	993	4,554	4,549	3,444	3,346
Accounts payable	24	35	77	83	80	79
Current portion of long-term debt	—	—	—	2	19	0
Total current liabilities	54	78	145	154	174	158
Long-term debt	—	0	885	888	875	794
Lease liability, non-current	1	2	9	10	13	14
Total liabilities	80	106	1,420	1,405	1,373	1,253
Retained earnings (accumulated deficit)	540	588	565	556	(536)	(544)
Total stockholders' equity	840	887	3,134	3,144	2,071	2,093
Total liabilities and equity	920	993	4,554	4,549	3,444	3,346
Common shares outstanding (cover page) millions of shares	107	108	216	217	217	218

† Share count changed about 2x in the period ending 2023-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (NEOG's year ends in late May)

In millions of dollars	FY 2021May 31, 2021	FY 2022May 31, 2022	FY 2023†May 31, 2023	FY 2024May 31, 2024	FY 2025May 31, 2025	FY 2026May 31, 2026
Net income (loss)	61	48	(23)	(9)	(1,092)	(8)
Stock-based compensation	6	7	10	14	17	13
Depreciation and amortization	21	24	88	117	119	116
Net cash from operating activities	81	68	41	35	58	83
Net cash from investing activities	(106)	(97)	201	(29)	(99)	71
Proceeds from long-term debt	—	—	0	0	450	0
Repayments of long-term debt	0	0	100	0	550	100
Net cash from financing activities	34	7	(118)	2	(2)	(99)
Net change in cash	9	(31)	119	7	(42)	57

† Share count changed about 2x in the period ending 2023-05-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Viridian Therapeutics	173	26	(93)*	113.6M	9.0 quarters	Q3 FY26 10-QSep 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.